Back to TEVA Stock Lookup

Teva Pharma (TEVA) –

Nov 26, 2014 11:26 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 26
Nov 26, 2014 11:13 AM Prof. Yitzhak Peterburg Elected Chairman of Teva’s Board of Directors
Nov 21, 2014 08:18 AM Teva Pharma (TEVA) Receives Positive CHMP Opinion for Rasagiline Ratiopharm as Idiopathic PD Treatment
Nov 18, 2014 01:04 PM Teva (TEVA), Valeant (VRX) Deal Unlikely, BMO Analyst Tells Bloomberg
Nov 18, 2014 09:54 AM Teva Pharma (TEVA) Active, Shares Gain
Nov 18, 2014 09:16 AM Teva Pharma (TEVA) Launches Liquid Formulation of TREANDA Injection
Nov 18, 2014 09:07 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 18
Nov 18, 2014 08:00 AM Teva Launches Liquid Formulation of TREANDA® (bendamustine HCI) Injection in U.S.
Nov 10, 2014 08:12 AM Teva Pharma (TEVA) PT Raised to $70 at Maxim Group
Nov 7, 2014 09:14 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 07
Nov 7, 2014 09:02 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 07
Nov 7, 2014 08:00 AM Teva Presents Positive Safety and Efficacy Data for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Nov 7, 2014 08:00 AM Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Nov 4, 2014 09:40 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 04
Nov 4, 2014 08:03 AM Teva Pharma (TEVA), Active Biotech Initiate ARPEGGIO Trial
Nov 4, 2014 08:00 AM Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington’s Disease Tria
Nov 3, 2014 08:09 AM RBC Capital Upgrades Teva Pharma (TEVA) to Outperform
Nov 3, 2014 07:00 AM BioTime’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macula
Oct 30, 2014 04:01 PM OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
Oct 30, 2014 02:00 PM Teva Pharma (TEVA) Price Target Raised to $64 at Deutsche Bank
Oct 30, 2014 10:32 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Oct 30
Oct 30, 2014 07:10 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Oct 30
Oct 30, 2014 07:04 AM Teva Pharma (TEVA) Tops Q3 EPS by 9c
Oct 30, 2014 07:03 AM Teva Reports Third Quarter 2014 Results
Oct 29, 2014 03:47 PM Trading Radar for 10/30: GoPro (GPRO), MasterCard (MA), LinkedIn (LNKD), Starbucks (SBUX) Report
Oct 14, 2014 12:48 PM Standpoint Research Upgrades Teva Pharma (TEVA) to Buy
Oct 9, 2014 04:07 PM Alexza Pharma (ALXA) Updates on Commercial Progress of ADASUVE in U.S. (TEVA)
Oct 8, 2014 10:06 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Oct 08
Oct 8, 2014 08:08 AM Teva Pharma (TEVA) Initiates Rolling NDA for CEP-33237
Oct 8, 2014 08:00 AM Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets
Oct 6, 2014 02:21 PM Form 6-K TEVA PHARMACEUTICAL INDU For: Oct 06
Oct 6, 2014 01:59 PM Teva to Report Third Quarter 2014 Financial Results on October 30, 2014
Oct 6, 2014 09:12 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Oct 06
Oct 6, 2014 08:39 AM Teva Pharma (TEVA) Completes Review of Core Therapeutic Areas; Will Discontinue 14 Pipeline Products
Oct 6, 2014 08:30 AM Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas
Oct 6, 2014 08:00 AM BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen® Designed to Treat Patients with Dry-AMD
Oct 3, 2014 01:24 PM Teva Pharma (TEVA) / Mylan (MYL) Combo Unlikely, Says Wells Fargo
Oct 3, 2014 08:04 AM Goldman Sachs Comments on Mylan (MYL) Following Yesterday's Rumors (TEVA) (ABT)
Oct 2, 2014 11:15 AM Standpoint Research Downgrades Teva Pharma (TEVA) to Hold
Sep 17, 2014 09:00 AM BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen® in Preclinical Animal Studies
Sep 16, 2014 06:30 AM OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-R
Sep 12, 2014 09:18 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Sep 12
Sep 12, 2014 09:00 AM Teva Presents Gene Expression Analysis at Joint Actrims-Ectrims Meeting Demonstrating Copaxone® (Glatiramer Acetate Injection) Has a Complex Profile
Sep 12, 2014 08:47 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Sep 12
Sep 12, 2014 08:14 AM Teva Pharma (TEVA), Active Biotech Update on Safety of Laquinimod Phase 2 as RRMS Treatment
Sep 12, 2014 08:00 AM Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
Sep 11, 2014 11:21 AM Form 6-K TEVA PHARMACEUTICAL INDU For: Sep 11
Sep 11, 2014 09:30 AM Teva Pharma (TEVA) Reports GLACIER Study Primary Endpoint Achieved
Sep 11, 2014 09:29 AM Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to D
Sep 10, 2014 02:30 PM Teva Pharma (TEVA) Reports Health Canada Approves Application for Generic Cipralex

Back to TEVA Stock Lookup